AbbVie (ABBV) Says Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients

Go back to AbbVie (ABBV) Says Second Phase 3 Induction Study Confirms Upadacitinib Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients

Second Phase 3 Induction Study Confirms Upadacitinib (RINVOQâ„¢) Improved Clinical, Endoscopic and Histologic Outcomes in Ulcerative Colitis Patients

February 22, 2021 8:45 AM EST

NORTH CHICAGO, Ill., Feb. 22, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that upadacitinib (45 mg, once daily) met the primary endpoint of clinical remission (per Adapted Mayo Score) and all ranked secondary endpoints in the Phase 3 induction study, U-ACCOMPLISH.1 In the study, 33 percent of... More